Analyst Comment

ExpreS2ion: Presentation of Q1 2026 report (Recording)

Today, ExpreS2ion Biotechnologies' management presented the financial results for Q1 2026, provided further insights into the recent pipeline developments with focus on the breast cancer, malaria and Nipah candidates, and shared the latest updates on the completed rights issue and the partnering outlook for ES2B-C001.

Watch the recording here:

Expres2ion - Q1 2026 Event

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 13:03, 28/05-2026

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.